Clinical trial
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
NCT00460798 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00460798 |
|---|---|
| Title | SUTENT® In The First Line Treatment Of Renal Cell Carcinoma |
| Official title | A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Cancer |
| Acronym | SUNIKA |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Other |
| Interventions | Sutent: observational study |
| Enrollment | 356 |
| Start date | Feb 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Apr 16, 2007 |
| Last update posted | Nov 16, 2010 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: